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Patients who have suffered from cerebral ischemia have a high risk of recurrent vascular
events. Predictive models based on classical risk factors typically have limited prognostic
value. Given that cerebral ischemia has a heritable component, genetic information might im-
prove performance of these risk models. Our aim was to develop and compare two models:
one containing traditional vascular risk factors, the other also including genetic information.
Methods and Results
We studied 1020 patients with cerebral ischemia and genotyped themwith the Illumina Immu-
nochip. Median follow-up time was 6.5 years; the annual incidence of new ischemic events (pri-
mary outcome, n=198) was 3.0%. The prognostic model based on classical vascular risk
factors had an area under the receiver operating characteristics curve (AUC-ROC) of 0.65
(95% confidence interval 0.61-0.69). When we added a genetic risk score based on prioritized
SNPs from a genome-wide association study of ischemic stroke (using summary statistics from
theMETASTROKE study which included 12389 cases and 62004 controls), the AUC-ROC re-
mained the same. Similar results were found for the secondary outcome ischemic stroke.
Conclusions
We found no additional value of genetic information in a prognostic model for the risk of is-
chemic events in patients with cerebral ischemia of arterial origin. This is consistent with a
complex, polygenic architecture, where many genes of weak effect likely act in concert to
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influence the heritable risk of an individual to develop (recurrent) vascular events. At pres-
ent, genetic information cannot help clinicians to distinguish patients at high risk for recur-
rent vascular events.
Introduction
Patients who suffered from cerebral ischemia have an increased (long-term) risk of new cere-
brovascular and cardiovascular events. The American Heart Association recommends the Fra-
mingham risk score as a prediction model for major vascular events.[1, 2] Recently this model
was compared with six other models in terms of calibration and discrimination.[3] Almost all
models slightly overestimated the risk for major events in low and high risk patients. Addition
of genetic information might improve these models, but so far this has not yet been evaluated.
Several studies have been performed with a candidate gene approach to find an association
between single nucleotide polymorphisms (SNPs) and first ischemic strokes, with often conflict-
ing results, possibly due to small sample sizes in earlier studies and heterogeneity of the stroke
subtypes. Two loci (PITX2 and ZFHX3) were found to be associated with atrial fibrillation and
cardioembolic stroke risk.[4, 5] Subsequently, two loci (9p21 andHDAC9) were identified as ro-
bust associations with large vessel stroke.[6, 7] These findings were recently confirmed in a meta-
analysis of genome-wide association studies (GWAS) carried out by the METASTROKE consor-
tium.[8] These common genetic polymorphisms account only for a small increase in disease risk,
suggesting that large sample sizes will be needed to find additional susceptibility alleles.[9]
Associations between genetic polymorphisms and recurrence of vascular events following
an initial episode of cerebral ischemia have received little attention. The aim of our study was
to assess the additional value of genetic information in prognostic models in a hospital based
cohort of patients who have suffered from cerebral ischemia of arterial origin (CIAO). We
benefited from continuing efforts in the international stroke genetics community by incorpo-
rating results from the METASTROKE study.[8] With the observed effect estimates for select-
ed SNPs (enriched for association with ischemic stroke), we calculated a genotype-based score
for each individual in our cohort. Because the data from the GWAS were collected indepen-
dently from our cohort, we were able to directly and rigorously assess the prognostic value of
our prediction models.
Methods
Study design and patient population
The rationale of this study is described elsewhere in detail.[10] We collected data of patients
with non-disabling cerebral ischemia of arterial origin, who were referred to the University
Medical Center Utrecht, The Netherlands and were included in the SMART (Second Manifes-
tations of Arterial disease) study, or the Utrecht Stroke Database (USDB). A detailed descrip-
tion of the SMART study was published previously.[11] Briefly, patients who gave their written
informed consent underwent a standardised vascular screening programme, including a health
questionnaire, laboratory assessment, and ultrasonography to investigate the prevalence of
additional vascular diseases. Patients were followed up with bi-annual questionnaires. In the
USDB extensive baseline data have been collected for consecutive patients visiting the Univer-
sity Medical Center Utrecht for TIA or stroke since 1991. Patient data was used anonymized in
our analyses. Blood samples were taken from 1999 onwards and stored in the Neurology Blood
Bank. Follow-up data were collected by contacting these patients or their general practitioners.
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Patients with non-atherosclerotic causes of cerebral ischemia or with potential source of embo-
lism in the heart were excluded from this study. We therefore included only patients with cere-
bral ischemia of arterial origin. For the current study, the data of 1125 patients were available.
These patients were included between April 1994 and May 2009.
Outcomes
The primary outcome event was defined as a composite of the first occurrence of myocardial in-
farction, ischemic stroke or vascular death not due to hemorrhage. Secondary outcome event was
recurrent ischemic stroke (Table 1). For potential outcome events reported by the patient we re-
trieved hospital discharge letters and the results of relevant laboratory and radiology examinations.
Three members of the SMARTOutcome Committee independently audited events on basis of
available information. This committee consisted of physicians from different departments. In case
of disagreement, consensus was reached by consulting other members of the Outcome Commit-
tee. Potential outcomes in patients included from the USDB were audited similarly.
Genotyping
DNA samples available from both studies and stored in a -70 degrees Celsius freezer were
transported to the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC,
Rotterdam, The Netherlands, where the samples were genotyped with the Illumina Immuno-
chip.[12] The goal of the Immunochip was to provide a cost-effective genotyping platform for
deep follow-up replication studies. It includes about 200,000 SNPs, selected in part on the basis
of association results (low p-values) from a wide range of GWAS of immune-related diseases
as well as the diseases covered by the second round of the Wellcome Trust Case Control Con-
sortium (WTCCC-2), including ischemic stroke (http://www.wtccc.org.uk/ccc2/wtccc2_
studies.shtml). About 2500 SNPs from an early analysis of the ischemic stroke GWAS by
WTCCC-2 were contributed to the Immunochip design. We used these specific SNPs for our
further analyses.
Quality control steps consisted of filtering of SNPs and individuals with>5%missing
data, followed by filtering of SNPs with a minor allele frequency (MAF)<1% or deviation from
Hardy-Weinberg equilibrium (HWE; p< 10−6). We then used individual-pairwise identity-by-
state estimates to remove (unknown) related and potentially contaminated samples. We pruned
Table 1. Definitions of outcome events.
Event Definition
Ischemic stroke Relevant clinical features that caused an increase in impairment of at
least one grade on the modified Rankin scale21 associated with a relevant
infarction on a repeat brain scan.
Myocardial infarction At least two of the following criteria:
1: Chest pain >20 min, not disappearing after administration of nitrates
2: ST elevation >1 mm in two following leads or a left bundle branch block
3:CK elevation of at least two times its normal value and an MB fraction
>5% of total CK
Vascular death: not due to
hemorrhage
Sudden death: unexpected coronary death occurring within 1 h after onset
of symptoms or within 24 h given convincing circumstantial evidence.
Terminal heart failure
Fatal myocardial infarction or ischemic stroke
Primary outcome was defined as all fatal and non-fatal ischemic events. Secondary outcome was ischemic
stroke separately.
doi:10.1371/journal.pone.0119203.t001
No Predictive Value of Genetics after Ischemic Stroke
PLOS ONE | DOI:10.1371/journal.pone.0119203 April 23, 2015 3 / 10
SNPs by their pairwise linkage disequilibrium to arrive at a set of independent SNPs. Data pro-
cessing and quality control filtering were performed in PLINK.[13] Principal components anal-
ysis was used to check genetic clustering of all individuals against reference individuals from the
HapMap.[14]
Individual genetic risk score
For each individual patient we calculated a genetic risk score on the basis of the genotypes of
1501 QC-passing SNPs and their effect sizes that were independently obtained from the GWAS
of ischemic stroke led by the METASTROKE consortium.[8] Using PLINK, we calculated the
genetic risk score as the sum of the ln(OR) multiplied by the number of risk alleles carried for
each SNP considered in a given individual, following a method described elsewhere. [15]
Statistical analysis
The prediction models were built with Cox regression analyses in SPSS. In univariable analysis
we calculated the hazard ratios and corresponding 95% confidence intervals (CI) of different
stroke risk factors. The different clinical variables included were adapted from a previous study,
in which they determined long term survival and recurrent vascular event risk in patients with
cerebral ischemia.[16] We then constructed the prediction model, in which we sequentially en-
tered variables from the patients’ history until no remaining candidate variable had a signifi-
cance level of<0.10 and into which we forced the genetic risk score based onMETASTROKE
effect estimates. Next we constructed receiver-operator characteristics (ROC) curves to compare
the discriminatory performance with its area under the curve (AUC) of the model with and
without genetic information. All analyses were done for the primary and secondary outcome.
Results
Baseline
Data were available of 1125 patients presenting with transient or non-disabling manifestations
of cerebral or retinal ischemia and with information on genetic variants. Of these, 105 patients
had to be excluded from further analysis because of genotyping quality concerns or unexpected
relatedness between patients. These patients were similar to the remaining patients with respect
to baseline characteristics (Table 2).
At baseline patients had a mean age of 63 years and 66% was male (Table 2). The index
event was a minor stroke in 53% of the patients, 35% had had a TIA and 12% suffered from an
ischemic ocular event. Almost 50% of the patients had hypertension and 20% suffered from an
earlier stroke. Patients with a recurrent ischemic vascular event had overall more risk factors
for vascular disease than patients who had no recurrence.
Follow up
The median follow-up time was 6.5 years (6630 person-years). The follow-up was complete in
99.5% of the patients. The annual risk of ischemic events was 3.0% (198 events). Half of the
events were a fatal or non-fatal ischemic stroke (98 patients), 65 events concerned fatal or non-
fatal myocardial infarction and the remaining 35 were other vascular death.
Prognostic value of classical vascular risk factors
The different AUC-ROC values for the primary and secondary outcomes are displayed in
Table 3 and for the primary outcome the ROC-curves are displayed in Fig 1. For the primary out-
come the prognostic model consisted of the variables age, sex, myocardial infarction, intermittent
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claudication, diabetes mellitus and vascular surgery. The AUC-ROC was 0.65 (95% CI 0.61–
0.69). For the secondary outcome, the AUC-ROC was 0.60 (95% CI 0.54–0.66), this included the
vascular risk factors age, myocardial infarction, and hypertension.
Prognostic value of classical risk factors and genetic risk score
The vascular risk factors used in these models remained the same as the ones used in the first
model. After addition of the genetic risk score the AUC-ROC for the primary outcome was es-
sentially identical to that of the model with only classical vascular risk factors. For cerebral is-
chemia the AUC-ROC showed similar patterns (Table 3).
Discussion
In our cohort of patients with cerebral ischemia of arterial origin we found no additional value
of genetic information in the prediction of new ischemic events including ischaemic stroke.
The overall prognostic performance of the known classical risk factors for vascular diseases is
poor (AUC-ROC 0.65; 95%CI 0.61–0.69), consistent with similar prediction models described
in the literature.[3] The inclusion of a genetic risk score based on SNPs that could be associated
with ischemic stroke did not result in a prognostic model that improved risk stratification.
Table 2. Baseline characteristics.
Included patients Excluded patients
1020 105
Patients with primary outcome Patients without primary outcome
198 822
Age (years) (mean, SD) 66 (10) 62 (11) 63 (11)
Male sex 150 (76%) 518 (63%) 68 (65%)
Qualifying diagnosis
TIA 75 (38%) 283 (34%) 30 (28%)
Stroke 93 (47%) 451 (55%) 66 (62%)
Transient Monocular Blindness 24 (12%) 79 (10%) 6 (6%)
Retinal infarction 6 (3%) 9 (1%) 3 (3%)
Subtype Qualifying diagnosis
Large vessel disease 141 (71%) 552 (67%) 57 (54%)
Small vessel disease 57 (29%) 270 (33%) 48 (46%)
History
Stroke 53 (27%) 161 (20%) 17 (16%)
Carotid surgery 14 (7%) 21 (3%) 3 (3%)
Myocardial infarction 37(19%) 80 (10%) 9 (9%)
Vascular surgery 51 (26%) 119 (15%) 16 (15%)
Hypertension 99 (50%) 391 (48%) 50 (47%)
Diabetes Mellitus 37 (19%) 106 (13%) 19 (18%)
Hyperlipidemia 60 (30%) 280 (34%) 36 (34%)
Cigarette smoking
Currently 35 (18%) 198 (24%) 28 (26%)
Never or ever 159 (81%) 559 (73%) 71 (67%)
Blood pressure (mm Hg)
Systolic (mean, SD) 157 (28) 149 (25) 153 (28)
Diastolic (mean, SD) 85 (14) 84 (13) 84 (14)
Glucose (mmol/L) (mean, SD) 6.6 (2.4) 6.4 (1.9) 6.5 (2.0)
* Patients were excluded because of quality concerns
doi:10.1371/journal.pone.0119203.t002
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As far as we know, our study is the first to characterize the prognostic value of genetic infor-
mation in the assessment of future risk for vascular events after cerebral ischaemia. Our cohort
comprises well phenotyped ischemic stroke patients from a single medical center with uniform
follow-up data. The origin from a single hospital could also be seen as a limitation with respect
Table 3. Cox proportional hazardmodels and AUC-ROC.
M1 M2
Indicator HR 95% CI HR 95% CI
Demographic characteristics
Male 1.47 1.06–2.04 1.35 0.86–2.11
Age 1.05 1.03–1.06 1.02 1.00–1.04
History
Myocardial infarction 1.78 1.25–2.55 1.72 1.03–2.87
Hypertension 1.08 0.82–1.43 1.56 1.05–2.33
Intermittent Claudication 1.76 1.14–2.72 1.55 0.80–2.97
Diabetes Mellitus 1.37 0.96–1.97 1.34 0.81–2.24
Vascular surgery 1.79 1.30–2.46 1.50 0.93–2.40
Genetic risk score 1.13 0.92–1.38 1.17 0.91–1.50
AUC-ROC
Only classical risk factors 0.65 0.61–0.69 0.60 0.54–0.65
Plus genetic risk core 0.66 0.61–0.70 0.60 0.54–0.66
Table displays univariable analyses of risk factors for vascular disease for different endpoints. The bold
numbers are accounted in the multivariable model with and without genetic risk scores. AUC-ROC = Area
Under Curve of the Receiver Operating Characteristics Curve. M1 = primary outcome. M2 = secondary
outcome, ischemic stroke
doi:10.1371/journal.pone.0119203.t003
Fig 1. ROC curves for the primary outcome. (a) based on classical risk factors only; (b) based on classical risk factors plus the genetic risk score.
doi:10.1371/journal.pone.0119203.g001
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to the generalisability of the results. However, we feel that our cohort is representative since the
results for classical risk factors for atherosclerosis affecting prognosis, like previous stroke, dia-
betes mellitus or hypertension, are consistent with other studies.
The sample size is a major limitation. We had to drop almost 10% of our population due
to quality concerns of the genetic data. These patients, however, had similar clinical charac-
teristics as the remaining patients. Furthermore we included only non-disabled patients on
the (predefined) basis that this patient group is the one most relevant, with the highest chance
of survival and long-term prospects for recovery, and therefore represents the main focus of
our study.
The selection of SNPs and the nature of the external training data set could be seen as a
limitation of our study. We were not aware of another dataset on patients with cerebral is-
chemia of arterial origin followed prospectively for the occurrence of ischemic events or
bleedings in whom also genetic data were available (which we could have used as an alter-
native training data set). We therefore decided to use the observed effect estimates from
the METASTROKE study, even though this study focused on prevalent (ischemic) stroke
cases in the population instead of the occurrence of recurrent vascular events. It is certainly
possible that genes influencing the risk of a first cerebral ischemic event differ from those
genes associated with long-term prognosis after an ischemic event. In addition, we only
used the effect estimates for all types of ischemic stroke instead of those for small and large
vessel stroke subtypes, because our sample was too small to look into individual subtypes
of stroke.
Our results illustrate the complexity of finding susceptibility alleles for a clinical pheno-
type that is so complex and heterogeneous such as ischemic stroke. To date, only a handful
of robust SNP associations have been identified for cardioembolic stroke (PITX2, ZFHX3),
large-artery atherosclerotic stroke (9p21, HDAC9), and more recently, for all subtypes of
stroke (12q24). [17–18]The approach to test the collective effects of many common variants
simultaneously has been successfully applied in complex traits such as schizophrenia and bi-
polar disorder [15]
We were only informed about the use of medication at baseline of the patients in this study.
Platelet function, response to pharmacotherapy and genetic factors may be associated with out-
come and recurrent risk. The debate about the role of aspirin resistance and the way patient tai-
lored treatment strategies could be implemented in daily practice is still ongoing.[19–21] The
same is true for other antithrombotic treatment strategies as, for example clopidogrel, for
which genetic association with its metabolism is reasonably well understood.[22]
Future stroke genetic studies might result in better risk prediction for different stroke sub-
types and recurrent events. It remains unresolved today, however, to what extent genetic vari-
ants of modest effect (even if many more are identified as a result of larger discovery efforts)
could contribute to prognostic models for such complex phenotypes as stroke above and be-
yond family history and traditional risk factors.
Integrity of research and reporting
The Ethics Committee of the hospital approved both studies (SMART and USDB) from which
we used the data. All patients included in these studies gave written informed consent prior
to inclusion.
The authors had full access to the data and take responsibility for its integrity. All authors
have read and agree to the manuscript as written. The authors declare that they have no con-
flict of interest.
The data of this study will be made available upon request
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